WallStSmart
INTS

Intensity Therapeutics, Inc. Common stock

NASDAQ: INTS · HEALTHCARE · BIOTECHNOLOGY

$5.21
+0.06% today

Updated 2026-05-06

Market cap
$13.80M
P/E ratio
P/S ratio
EPS (TTM)
$-8.56
Dividend yield
52W range
$5 – $44
Volume
0.0M

Intensity Therapeutics, Inc. Common stock (INTS) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-50.9%
Last 4 quarters
Revenue YoY growth
-208.3%
Most recent quarter
EPS YoY growth
-3.3%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-13.8%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-14.3%
2026-03-12
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-12$-1.21-2317.2%$7.91$6.78-14.3%
2025-11-07$-0.06+0.0%$0.49$0.42-13.3%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.05$-1.21-2317.2%$-26000.00-208.3%
2025-09-30$-0.06$-0.06+0.0%
2025-06-30$-0.16$-0.13+18.8%
2025-03-31$-0.18$-0.22-22.2%
2024-12-31$-0.22$-1.17-431.8%$24000.00-91.5%
2024-09-30$-0.31$-0.25+18.0%
2024-06-30$-0.32$-0.36-12.5%
2024-03-31$-0.34$-0.34+0.0%
2023-12-31$-0.18$-0.23-28.6%$282216.00
2023-09-30$-0.09$-0.17-88.9%
2023-06-30$-0.40$-1.43-257.5%
2023-03-31$-0.39$-0.39+0.0%

Frequently asked questions

Has Intensity Therapeutics, Inc. Common stock beaten earnings estimates?
Intensity Therapeutics, Inc. Common stock has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -50.9% over the last 4 quarters.
How does INTS stock react to earnings?
INTS stock has moved an average of -13.8% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Intensity Therapeutics, Inc. Common stock's revenue growth rate?
Intensity Therapeutics, Inc. Common stock reported year-over-year revenue growth of -208.3% in its most recent quarter, with EPS growing -3.3% year-over-year.